- Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis…
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company…
Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney…
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the…
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of…
New program extends leadership of Y90 for treatment planningCHICAGO, March 25, 2024 (GLOBE NEWSWIRE) -- TeleDaaS™, PLLC, the leading dosimetry-as-a-service…
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight…
Matinas' Positivein vivo Safety Data with its Oral LNC-Docetaxel Formulation Oral LNC-Docetaxel is significantly less toxic than IV-Docetaxel Daily oral…
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or…